Related Experiment Videos
Melatonin improves sleep-wake patterns in psychomotor retarded children
1Sleep Laboratory, Technion-Israel Institute of Technology, Haifa, Israel.
Insights
Melatonin supplements significantly improved sleep patterns in children with severe psychomotor retardation. This treatment increased nighttime sleep duration and efficiency, aiding their irregular sleep-wake cycles.
Area of Science:
- Pediatric Neurology
- Sleep Medicine
- Developmental Pediatrics
Background:
- Children with severe psychomotor retardation often exhibit irregular sleep-wake patterns.
- Abnormally low urinary sulfatoxymelatonin levels, with no diurnal variation, were observed in these children.
- This suggests a potential disruption in endogenous melatonin production or regulation.
Purpose of the Study:
- To investigate the efficacy of melatonin supplementation in improving sleep-wake patterns in children with severe psychomotor retardation.
- To assess the impact of melatonin on nighttime and daytime sleep duration and overall sleep efficiency.
- To evaluate changes in sleep patterns following a standardized melatonin treatment regimen.
Main Methods:
- Five children with severe psychomotor retardation (mean age 8.2 years) were monitored using wrist actigraphy for one week.
- Participants received a 3 mg dose of melatonin daily.
- Actigraphy was repeated after the treatment period, and urinary sulfatoxymelatonin levels were measured in three participants.
Main Results:
- Melatonin treatment significantly increased nighttime sleep duration (from 5.9 to 7.3 hours, P<0.01).
- Sleep efficiency improved significantly from 69.3% to 88.3% (P<0.01).
- Daytime sleep duration decreased (from 3.2 to 1.7 hours, P<0.05), with no significant change in total 24-hour sleep time.
Conclusions:
- Administration of 3 mg melatonin effectively improved sleep-wake patterns in children with severe psychomotor retardation.
- Melatonin supplementation can be a beneficial therapeutic option for managing sleep disturbances in this population.
- Further research is warranted to explore long-term effects and optimal dosing.
Abstract:
Five children with severe psychomotor retardation (mean age 8.2+/-3.6 years) and irregular sleep-wake patterns underwent 1 week of wrist actigraphic monitoring before and after treatment with 3 mg melatonin. Three underwent multiple measurements of urinary sulfatoxymelatonin levels. Urine sulfatoxymelatonin levels were abnormally low, without any significant day/night differences. Melatonin treatment increased nighttime sleep from 5.9+/-0.8 to 7.3+/-0.5 hours (paired t test, P<0.01) and sleep efficiency from 69.3%+/-6.2% to 88.3%+/-2.3% (P<0.01). Daytime sleep decreased from 3.2+/- 1.2 to 1.7+/-1.2 hours (P<0.05). Thus, no change in 24-hour total sleep time (9.1+/-1.5 vs. 9.0+/-1.6 hours) occurred. Administration of 3 mg melatonin to five severely psychomotor retarded children resulted in a significant improvement in their sleep-wake patterns.